Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia

In October 2020, the FDA granted regular approval to venetoclax (ABT-199) in combination with hypomethylating agents for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or in patients with comorbidities precluding intensive chemotherapy. The treatment response to venetoclax...

Descripción completa

Detalles Bibliográficos
Autores principales: Seipel, Katja, Brügger, Yvo, Mandhair, Harpreet, Bacher, Ulrike, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604078/
https://www.ncbi.nlm.nih.gov/pubmed/36293442
http://dx.doi.org/10.3390/ijms232012587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604078/
https://www.ncbi.nlm.nih.gov/pubmed/36293442
http://dx.doi.org/10.3390/ijms232012587

Ejemplares similares